A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach - FLOT

Trial Profile

A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach - FLOT

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Capecitabine; Cisplatin; Epirubicin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2018 Planned End Date changed from 1 Jun 2017 to 1 Sep 2018.
    • 05 Jun 2018 Results (n=100) assessing the prognostic role of PD-L1 mRNA expression presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 01 Nov 2017 Primary endpoint (median overall survival)has been met as per the results presented at the 25th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top